Breaking News Instant updates and real-time market news.

FB

Facebook

$139.74

-3.9 (-2.72%)

12:34
12/19/18
12/19
12:34
12/19/18
12:34

Washington D.C. sues Facebook for 'failing to protect' user data

Washington D.C. Attorney General Karl Racine today sued Facebook for "failing to protect its users' data, enabling abuses like one that exposed nearly half of all District residents' data to manipulation for political purposes during the 2016 election." In its lawsuit, the Office of the Attorney General alleges Facebook's "lax oversight and misleading privacy settings allowed, among other things, a third-party application to use the platform to harvest the personal information of millions of users without their permission and then sell it to a political consulting firm." In the run-up to the 2016 presidential election, some Facebook users downloaded a "personality quiz" app which also collected data from the app users' Facebook friends without their knowledge or consent, says Racine in a press release. The app's developer then sold this data to Cambridge Analytica, which used it to help presidential campaigns target voters based on their personal traits, he adds. "Facebook took more than two years to disclose this to its consumers," says the attorney general. The Office of the Attorney General is seeking monetary and injunctive relief, including relief for harmed consumers, damages, and penalties to the District. Shares of Facebook are down 3%, or $4.77, to $138.89 in midday trading. Reference Link

FB Facebook
$139.74

-3.9 (-2.72%)

12/12/18
BOFA
12/12/18
NO CHANGE
Target $190
BOFA
Buy
Facebook testing search ads may unlock new revenue stream, says BofA/Merrill
BofA/Merrill analyst Justin Post kept his Buy rating and $190 price target on Facebook (FB), saying there is potential for "high value search activity" on its platform if its testing of search ads within the Marketplace section - as reported by TechCrunch - bears fruit. The analyst notes that the report anticipates the search ad testing to be rolled out with a small set of auto and e-commerce advertisers, modeling that the company could generate up to $5B in annual search related ad revenue under the assumption of offering a 75% discount to Google's (GOOGL) revenue per search. Post maintains his positive view on Facebook and its monetization opportunities.
12/10/18
DBAB
12/10/18
NO CHANGE
DBAB
Buy
Facebook valuation 'extremely attractive' at current levels, says Deutsche Bank
Facebook remains the best risk/reward in large cap internet given the potential for core engagement to stabilize, for monetization in the Stories format to drive a potential re-acceleration in growth in mid-2019, for the negative news cycle to abate and given the "extremely attractive" current valuation, Deutsche Bank analyst Lloyd Walmsley tells investors in a research note. The analyst is encouraged that on top of Facebook's "relatively aggressive" share buyback to-date, the board expanded the repurchase authorization again by an additional $9B. He reiterates a Buy rating on Facebook shares.
12/06/18
12/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. LG Display (LPL) initiated with a Buy at Citi. 2. Twitter (TWTR) and Alphabet (GOOG, GOOGL) were initiated with a Buy at Guggenheim, while Snap (SNAP) and Facebook (FB) were initiated with a Neutral. 3. Apache (APA) initiated with an Overweight at Stephens. 4. CorMedix (CRMD) initiated with a Buy at Roth Capital. 5. Protagonist Therapeutics (PTGX) initiated with a Buy at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/06/18
12/06/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Stifel with analyst Scott Devitt saying Facebook has made too many enemies, including politicians, regulators, technology leaders, consumers, and employees, to not experience "long-term negative ramifications on its business." 2. Conatus (CNAT) downgraded to Hold from Buy at Stifel with analyst Stephen Willey saying the Encore-PH trial missed its pre-specified primary endpoint but post-hoc analyses demonstrated a trend towards statistically significant/emricasan-mediated improvements in patients with compensated cirrhosis and elevated baseline hepatic venous pressure gradient values. 3. BHP Billiton (BHP) downgraded to Neutral from Overweight at JPMorgan with analyst Lyndon Fagan saying the stock has outperformed Rio Tinto (RIO) by 10% year-to-date, and is now trading "within range of our valuation." 4. Toll Brothers (TOL) downgraded to Sector Perform from Outperform at RBC Capital with analyst Michael Dahl citing a "sharper than expected weakness in orders and likelihood of further near-term declines," with softer margin assumptions attributed to a weaker outlook for orders. 5. Bluebird Bio (BLUE) downgraded to Neutral from Overweight at Piper Jaffray with analyst Tyler Van Buren saying the company is "incredibly innovative" company and bb2121 and LentiGlobin are essentially curing some patients, but the benefits "are not without serious risks." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

LNXSF

Lanxess

$0.00

(0.00%)

07:51
10/22/19
10/22
07:51
10/22/19
07:51
Downgrade
Lanxess rating change  »

Lanxess downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNW

Genworth

$4.31

0.01 (0.23%)

07:51
10/22/19
10/22
07:51
10/22/19
07:51
Hot Stocks
Genworth receives feedback from Canadian regulators regarding transaction »

Genworth Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

TREE

LendingTree

$317.86

3.4 (1.08%)

07:48
10/22/19
10/22
07:48
10/22/19
07:48
Recommendations
LendingTree analyst commentary  »

LendingTree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 13

    Nov

  • 19

    Nov

EQM

EQT Midstream Partners

$32.99

-0.2 (-0.60%)

, EQT

EQT Corporation

$9.54

-0.175 (-1.80%)

07:48
10/22/19
10/22
07:48
10/22/19
07:48
Hot Stocks
EQT Midstream Partners-owned MVP says project work will be 90% complete by 2020 »

Mountain Valley announced…

EQM

EQT Midstream Partners

$32.99

-0.2 (-0.60%)

EQT

EQT Corporation

$9.54

-0.175 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 05

    Nov

SNN

Smith & Nephew

$43.65

-4.165 (-8.71%)

07:48
10/22/19
10/22
07:48
10/22/19
07:48
Recommendations
Smith & Nephew analyst commentary  »

Smith & Nephew CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMC

Vulcan Materials

$146.64

0.5 (0.34%)

07:47
10/22/19
10/22
07:47
10/22/19
07:47
Initiation
Vulcan Materials initiated  »

Vulcan Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BBIO

BridgeBio

$18.54

0.29 (1.59%)

07:47
10/22/19
10/22
07:47
10/22/19
07:47
Hot Stocks
BridgeBio announces presentation of data from subsidiaries studies »

BridgeBio Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEL

TE Connectivity

$93.74

0.885 (0.95%)

07:45
10/22/19
10/22
07:45
10/22/19
07:45
Initiation
TE Connectivity initiated  »

TE Connectivity initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

MBRX

Moleculin Biotech

$1.07

-0.005 (-0.47%)

07:45
10/22/19
10/22
07:45
10/22/19
07:45
Hot Stocks
Moleculin Biotech raises Annamycin production »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEP

NextEra Energy Partners

$51.04

-0.54 (-1.05%)

07:43
10/22/19
10/22
07:43
10/22/19
07:43
Earnings
Breaking Earnings news story on NextEra Energy Partners »

NextEra Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Dec

AX

Axos Financial

$29.97

0.54 (1.83%)

07:43
10/22/19
10/22
07:43
10/22/19
07:43
Hot Stocks
Newbridge Securities enters five-year clearing agreement with Axos Clearing »

Newbridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 06

    Nov

  • 04

    Dec

  • 05

    Dec

CVA

Covanta

$17.06

0.31 (1.85%)

07:42
10/22/19
10/22
07:42
10/22/19
07:42
Downgrade
Covanta rating change  »

Covanta double downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

APH

Amphenol

$100.40

1.35 (1.36%)

07:42
10/22/19
10/22
07:42
10/22/19
07:42
Initiation
Amphenol initiated  »

Amphenol initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

MAIN

Main Street

$42.50

0.23 (0.54%)

07:41
10/22/19
10/22
07:41
10/22/19
07:41
Downgrade
Main Street rating change  »

Main Street downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

ASND

Ascendis Pharma

$103.39

4.25 (4.29%)

, OPK

Opko Health

$2.12

0.03 (1.44%)

07:40
10/22/19
10/22
07:40
10/22/19
07:40
Recommendations
Ascendis Pharma, Opko Health, Pfizer analyst commentary  »

Ascendis Pharma price…

ASND

Ascendis Pharma

$103.39

4.25 (4.29%)

OPK

Opko Health

$2.12

0.03 (1.44%)

PFE

Pfizer

$36.45

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Dec

CPE

Callon Petroleum

$3.71

-0.12 (-3.13%)

, CRZO

Carrizo Oil & Gas

$7.29

-0.18 (-2.41%)

07:40
10/22/19
10/22
07:40
10/22/19
07:40
Hot Stocks
Callon Petroleum files presentation highlighting benefits of Carrizo deal »

Callon Petroleum Company…

CPE

Callon Petroleum

$3.71

-0.12 (-3.13%)

CRZO

Carrizo Oil & Gas

$7.29

-0.18 (-2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 14

    Nov

  • 14

    Nov

BAND

Bandwidth

07:39
10/22/19
10/22
07:39
10/22/19
07:39
Upgrade
Bandwidth rating change  »

Bandwidth upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ARCC

Ares Capital

$18.70

0.14 (0.75%)

07:39
10/22/19
10/22
07:39
10/22/19
07:39
Downgrade
Ares Capital rating change  »

Ares Capital downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

FRPT

Freshpet

$49.68

0.05 (0.10%)

07:39
10/22/19
10/22
07:39
10/22/19
07:39
Upgrade
Freshpet rating change  »

JPMorgan upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 19

    Nov

  • 20

    Nov

CHCO

City Holding

$79.30

1.94 (2.51%)

07:39
10/22/19
10/22
07:39
10/22/19
07:39
Earnings
City Holding reports Q3 EPS $1.36, consensus $1.32 »

Reports Q3 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCC

Owl Rock

$16.90

-0.08 (-0.47%)

07:38
10/22/19
10/22
07:38
10/22/19
07:38
Downgrade
Owl Rock rating change  »

Owl Rock downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

CPE

Callon Petroleum

$3.71

-0.12 (-3.13%)

, CRZO

Carrizo Oil & Gas

$7.29

-0.18 (-2.41%)

07:38
10/22/19
10/22
07:38
10/22/19
07:38
Hot Stocks
Paulson & Co. reiterates opposition to Carrizo deal »

Paulson & Co., as…

CPE

Callon Petroleum

$3.71

-0.12 (-3.13%)

CRZO

Carrizo Oil & Gas

$7.29

-0.18 (-2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 14

    Nov

  • 14

    Nov

LMT

Lockheed Martin

$373.16

0.54 (0.14%)

07:38
10/22/19
10/22
07:38
10/22/19
07:38
Hot Stocks
Lockheed Martin sees FY20 sales $62.0B, consensus $62.82B »

The company said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

RVNC

Revance

$15.67

0.495 (3.26%)

07:37
10/22/19
10/22
07:37
10/22/19
07:37
Conference/Events
Revance management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 21

    Nov

AAOI

Applied Optoelectronics

$10.83

-0.02 (-0.18%)

07:37
10/22/19
10/22
07:37
10/22/19
07:37
Downgrade
Applied Optoelectronics rating change  »

Applied Optoelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.